Treats all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). ANDA 40177, held by Pharm Assoc. Trihexyphenidyl Hydrochloride.
As of Nov 16, 2026, ANDA 40177 (Trihexyphenidyl Hydrochloride), held by Pharm Assoc, was first approved by FDA on Apr 17, 1997, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trihexyphenidyl Hydrochloride2MG/5ML · elixir;oral | Trihexyphenidyl Hydrochloride | Rx |
| Jun 30, 2011 | Supplement 3Labeling | Approved | None posted |
| Oct 4, 2010 | Supplement 2Labeling | Approved | None posted |
| Apr 17, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters